The literature on risk factors for cardiometabolic diseases showed that lutein might be beneficial for atherosclerosis and inflammatory markers , but there were inconsistent associations with blood pressure , adiposity , insulin resistance , and blood lipids .
CONCLUSIONS Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health .
BACKGROUND The antioxidant lutein is suggested as being beneficial to cardiometabolic health because of its protective effect against oxidative stress , but evidence has not systematic ally been evaluated .
OBJECTIVE We aim ed to evaluate systematic ally the effects of lutein ( intake or concentrations ) on cardiometabolic outcomes in different life stages .
Lutein-fortified infant formula fed to healthy term infants: evaluation of growth effects and safety
Background / Objectives Breast milk contains lutein derived from the mother 's diet . This carotenoid is currently not added to infant formula , which has a small and variable lutein content from innate ingredients . This study was conducted to compare the growth of infants fed lutein-fortified infant formula  with that of infants fed infant formula without lutein fortification . Subjects/ Methods This 16-week study was prospect i ve , r and omized , controlled , and double-blind with parallel groups of healthy term infants fed either control formula ( Wyeth S-26 Gold  , design ated as Gold ) or experimental formula ( Wyeth S-26 Gold fortified with lutein at 200 mcg/l , design ated as Gold + Lutein ) . Two hundred thirty-two ( 232 ) infants ≤ 14 days postnatal age were r and omized and 220 ( 94.8 % ) completed the study .  Weight ( g ) , head circumference ( cm ) , and length ( cm ) were measured at Weeks 4 , 8 , 12 , and 16 . The primary endpoint was weight gain ( g/day ) from baseline to Week 16 . Safety was assessed through monitoring of study events ( SEs ) throughout the study and evaluation of selected blood chemistry tests performed at Week 16 . Results Infants in both treatment groups demonstrated appropriate growth . No differences between treatment groups were found in any of the measures of growth at any of the measurement time points . Both study formulas were well tolerated . The mean values of all measured blood chemistry parameters fell within the modified normal ranges for infants , and the values for both groups for any measured parameter were similar . Conclusions Infants fed lutein-fortified S-26 Gold  demonstrated growth equivalent to that of infants fed unfortified lutein formula
The literature on risk factors for cardiometabolic diseases showed that lutein might be beneficial for atherosclerosis and inflammatory markers , but there were inconsistent associations with blood pressure , adiposity , insulin resistance , and blood lipids .
CONCLUSIONS Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health .
BACKGROUND The antioxidant lutein is suggested as being beneficial to cardiometabolic health because of its protective effect against oxidative stress , but evidence has not systematic ally been evaluated .
OBJECTIVE We aim ed to evaluate systematic ally the effects of lutein ( intake or concentrations ) on cardiometabolic outcomes in different life stages .